822 A1A North
Suite 306
Ponte Vedra, FL 32082
United States
904 300 0701
https://www.cadrenal.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 4
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Quang X. Pham | Chairman & CEO | 967k | S.O. | 1965 |
Mr. Matthew K. Szot CPA, CPA | Chief Financial Officer | 594,89k | S.O. | 1974 |
Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer | 528,69k | S.O. | 1958 |
Mr. Jeffrey Cole | Chief Operating Officer | S.O. | S.O. | S.O. |
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
L’ISS Governance QualityScore de Cadrenal Therapeutics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..